Increased Acylation Stimulating Protein Concentrations in Nonalcoholic Fatty Liver Disease are Associated with Insulin Resistance

Yesilova, Zeki; Ozata, Metin; Oktenli, Cagatay; Bagci, Sait; Ozcan, Ayhan; Sanisoglu, S. Yavuz; Uygun, Ahmet; Yaman, Halil; Karaeren, Necmettin; Dagalp, Kemal
April 2005
American Journal of Gastroenterology;Apr2005, Vol. 100 Issue 4, p842
Academic Journal
OBJECTIVES: As acylation stimulating protein (ASP) acts on adipocytes mainly as a paracrine factor to increase triglyceride synthesis and storage; hypothetically, it may play a similar role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).METHODS: Forty-six male patients with NAFLD (group A), age-matched 30 male patients with chronic viral hepatitis (group B) and 30 age-matched and body mass index (BMI)-matched healthy male subjects were enrolled in the study.RESULTS: Among the NAFLD patients, 10 patients (24.4%) had simple steatosis and 36 patients (69.6%) had nonalcoholic steatohepatitis (NASH). The mean levels of ASP, complement 3, insulin, C-peptide, HOMA-IR, triglyceride, and very low-density lipoprotein (VLDL) were significantly higher in group A patients than both controls and group B. ASP levels correlated significantly in a positive manner with BMI, insulin, and HOMA-IR.CONCLUSIONS: Dysregulation of the ASP pathway may have important metabolic consequences in NASH and is associated with insulin resistance.(Am J Gastroenterol 2005;100:1–8)


Related Articles

  • Molecular pathways in non-alcoholic fatty liver disease. Berlanga, Alba; Guiu-Jurado, Esther; Porras, José Antonio; Auguet, Teresa // Clinical & Experimental Gastroenterology;2014, Vol. 7, p221 

    Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological change characterized by the accumulation of triglycerides in hepatocytes and has frequently been associated with obesity, type 2 diabetes mellitus, hyperlipidemia, and insulin resistance. It is an increasingly recognized...

  • Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Ying Qin; Ya-ping Tian // Lipids in Health & Disease;2010, Vol. 9, p78 

    Background: Non-alcoholic fatty liver disease (NAFLD), which is characterized by hepatic steatosis, can be reversed by early treatment. Several case reports have indicated that the administration of recombinant growth hormone (GH) could improve fatty liver in GH-deficient patients. Here, we...

  • Role of -55CT polymorphism of UCP3 gene on non alcoholic fatty liver disease and insulin resistance in patients with obesity. Aller, R.; De Luis, D. A.; Izaola, O.; Sagrado, M. González; Conde, R.; Alvarez, T.; Pacheco, D.; Velasco, M. C. // Nutricion Hospitalaria;jul-ago2010, Vol. 25 Issue 4, p572 

    Background and aims: Some studies have pointed to a role of UCP3 in the regulation of biochemical and fat parameters in overweight patients. The aim of our study was to investigate the influence of -55CT polymorphism of UCP3 gene (rs1800849) on histological changes and insulin resistance in...

  • Models for Non-Alcoholic Fatty Liver Disease: A Link with Vascular Risk. Xirouchakis, E.; Sigalas, A.; Manousou, P.; Calvaruso, V.; Pleguezuelo, M.; Corbani, A.; Maimone, S.; Patch, D.; Burroughs, A. K. // Current Pharmaceutical Design;Feb2008, Vol. 14 Issue 4, p378 

    Non alcoholic fatty liver disease (NAFLD) is often part of the metabolic syndrome which includes central obesity, dyslipidaemia, insulin resistance/type 2 diabetes mellitus and hypertension. In turn, NAFLD may be associated with an increased vascular risk. Several experimental models which...

  • Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis. Medina, Jesús; Fernández-Salazar, Luis I.; García-Buey, Luisa; Moreno-Otero, Ricardo // Diabetes Care;Aug2004, Vol. 27 Issue 8, p2057 

    Nonalcoholic steatohepatitis (NASH) represents an advanced stage of fatty liver disease developed in the absence of alcohol abuse. Its increasing prevalence in western countries, the diagnostic difficulties by noninvasive tests, and the possibility of progression to advanced fibrosis and even...

  • Hepatic steatosis in obese Chinese children. Chanh, D. F. Y.; Li, A. M.; Chu, W. C. W.; Chan, M. H. M.; Wong, E. M. C.; Liu, E. K. H.; Chan, T. H. S.; Yin, J.; Lam, C. W. K.; Fok, T. F.; Nelson, E. A. S. // International Journal of Obesity & Related Metabolic Disorders;Oct2004, Vol. 28 Issue 10, p1257 

    OBJECTIVES: The aims of our study were: (1) to determine the prevalence of asymptomatic hepatic steatosis and presumed nonalcoholic steatohepatitis, in our local population of obese Chinese children referred for medical assessment; and (2) to assess the correlation between severity of...

  • Impact of Steatosis on Insulin Secretion in Chronic Hepatitis C Patients. Narita, Ryoichi; Abe, Shintaro; Tabaru, Akinari; Otsuki, Makoto // American Journal of Gastroenterology;Oct2007, Vol. 102 Issue 10, p2173 

    OBJECTIVES: Liver steatosis is frequently observed in patients with chronic hepatitis C (CHC) and is an identified risk factor for progression of liver fibrosis. This study aimed to evaluate the relationship between steatosis and host/viral factors, and the correlation between steatosis and...

  • Influence of G1359A polimorphysm of the cannabinoid receptor gene (CNR1) on insulin resistance and adipokines in patients with non alcoholic fatty liver disease. Aller, R.; de Luis, D. A.; Pacheco, D.; Velasco, M. C.; Conde, R.; Izaola, O.; González Sagrado, M. // Nutricion Hospitalaria;sep/oct2012, Vol. 27 Issue 5, p1637 

    Background: Considering the evidence that endogenous cannabinoid system plays a role in metabolic aspects of body weight and metabolic syndrome components such as non alcoholic fatty liver disease (NAFLD). The aim of our study was to investigate the influence of this polymorphism on insulin...

  • Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. Savage, David B.; Cheol Soo Choi; Samuel, Varman T.; Zhen-Xiang Liu; Dongyan Zhang; Wang, Amy; Xian-Man Zhang; Cline, Gary W.; Xing Xian Yu; Geisler, John G.; Bhanot, Sanjay; Monia, Brett P.; Shulman, Gerald I.; Choi, Cheol Soo; Liu, Zhen-Xiang; Zhang, Dongyan; Zhang, Xian-Man; Yu, Xing Xian // Journal of Clinical Investigation;Mar2006, Vol. 116 Issue 3, p817 

    Hepatic steatosis is a core feature of the metabolic syndrome and type 2 diabetes and leads to hepatic insulin resistance. Malonyl-CoA, generated by acetyl-CoA carboxylases 1 and 2 (Acc1 and Acc2), is a key regulator of both mitochondrial fatty acid oxidation and fat synthesis. We used a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics